港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

555.407

-19.420-3.38%

漲家數：3

跌家數：28

平家數：3

市盈率：- -

高：575.370

開：574.827

低：551.244

收：574.827

成交量：7,591.26萬

成交額：15.75億

市值：3,459.51億

流通市值：3,100.86億

資料載入中...

總覽新聞資訊

創新藥向上還是向下：BD交易爆發、大摩持續唱多板塊仍處調整期

每日经济新闻

中國抗體-B(03681)：SM17用於治療IBD的IND獲NMPA批准

首付款五千萬美元，和鉑醫藥一款單抗產品達成授權協議及股權合作

心通醫療-B(02160.HK)股份合併生效

微創心通-B(02160)：股份合併生效

春節文旅消費創新高，復星主業基本盤穩固馬年展現強勁增長勢頭

凤凰网财经

創新藥企業員工薪酬TOP100來了（附名單）

MedTrend医趋势

科濟藥業-B(02171.HK)擬3月6日舉行董事會會議以審批年度業績

雲頂新耀(01952)股東特別大會通過商業化服務協議等決議案

康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏增加特應性皮炎(AD)適應症中國上市許可申請獲受理並獲納入優先審評

聖泉集團（605589）披露收購控股子公司尚博醫藥部分股權暨關聯交易公告，2月24日股價上漲4.17%

復宏漢霖(02696.HK)與雅培製藥就「漢斯狀」銷售新增許可區域

阿斯达克财经

康希諾生物(06185)：曼海欣®獲得《藥品補充申請批准通知書》

恒瑞醫藥：1類創新藥SHR-1918注射液獲受理並納入優先審評程序

阿斯达克财经

故鄉煙火經濟｜生產線滿負荷運轉，千名醫藥人春節守崗保供

每日沽空追蹤 | 沛嘉醫療-B 02月24日沽空量成交2.6萬股，沽空比例為5.75%

智通AH統計|2月24日

先瑞達醫療－Ｂ(06669)股價下跌5.039%，現價港幣$13.38

阿斯达克财经

浙江醫藥(600216.SH)擬參投合夥企業投向銀髮經濟/醫藥大健康領域

四川天府新區、金牛區公開招聘

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":555.40704,"timestamp":1771920487216,"preClose":574.827,"halted":0,"volume":75912636,"delay":0,"changeRate":-0.033784,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-19.419983,"latestTime":"02-24 16:00:00","open":574.827,"high":575.3701,"low":551.2441,"amount":1574615994,"amplitude":0.041971,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1771983000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1771896600000,1771905600000],[1771909200000,1771920000000]],"pbRate":5.026953,"peRate":-40.55114,"turnoverRate":0.002847,"increases":2,"decrements":30,"flats":0,"marketCap":345950625792,"floatMarketCap":310085645232},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":575.3701,"amplitude":0.041971,"preClose":574.827,"low":551.2441,"pbRate":"5.026953","latestPrice":555.40704,"volume":75912636,"delay":0,"open":574.827,"prevYearClose":556.26263,"prevWeekClose":571.129,"prevMonthClose":555.241,"prevQuarterClose":556.263,"fiveDayClose":551.442,"twentyDayClose":569.48,"sixtyDayClose":594.047,"secType":"PLATE","market":"HK","turnoverRate":0.002847,"peRate":-40.55114,"marketCap":345950625792,"floatMarketCap":310085645232,"timestamp":1771920487216,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":3,"down":28,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613105057","title":"創新藥向上還是向下：BD交易爆發、大摩持續唱多 板塊仍處調整期","url":"https://stock-news.laohu8.com/highlight/detail?id=2613105057","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613105057?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 22:26","pubTimestamp":1771943203,"startTime":"0","endTime":"0","summary":"2026年，我国创新药出海延续高景气度，最近两天先为达、前沿生物及和铂医药接连达成三笔BD（商务拓展）交易。医药魔方NextPharma数据库显示，截至2月15日（春节假期期间暂未新增交易事件），中国创新药已发生39起license-out（对外授权）交易事件，首付款约29.53亿美元，总金额超490亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243653031028.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243653031028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0106261372.USD","LU1791710582.SGD","BK4581","LU2347655156.SGD","LU1244550494.USD","LU1732800096.USD","LU1244550221.USD","LU1162221912.USD","LU1363072403.SGD","LU1989772840.SGD","BK4127","LU0320765646.SGD","BK1161","LU2089284900.SGD","LU0234570918.USD","LU2357305700.SGD","LU1791710400.SGD","LU0006306889.USD","LU1074936037.SGD","LU0314104364.USD","LU2089283258.USD","LU0225283273.USD","LU1668664300.SGD","BK4585","LU1548497426.USD","159992","LU2133065610.SGD","LU0557290698.USD","LU0882574139.USD","BK4534","BK4588","LU0971096721.USD","LU2023251221.USD","LU0106831901.USD","LU0912757837.SGD","LU0795875169.SGD","06978","LU1720051108.HKD","BK4516","IE00BKVL7J92.USD","LU2028103732.USD","BK1574","LU0528227936.USD","LU0158827781.USD","LU0795875086.SGD","LU2271345857.HKD","LU0158827948.USD","LU0098860793.USD","LU0267386448.USD","LU1720051017.SGD"],"gpt_icon":0},{"id":"2613717630","title":"中國抗體-B(03681)：SM17用於治療IBD的IND獲NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717630","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613717630?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 22:01","pubTimestamp":1771941713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 公布，于2026年2月24日，公司同类首创治疗产品SM17用于治疗炎症性肠病患者的新药临床试验申请已获中国国家药品监督管理局批准。公司已完成针对使用SM17皮下注射剂型的健康志愿者I期桥接实验的随访。该机制使SM17成为UC有前景的治疗候选药物，其中已证实IL-25发挥促炎作用。公司进一步认为，靶向2型炎性通路上游调控因子的治疗策略可支持SM17成为用于治疗AD及IBD的具差异化、安全性更佳且有效的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1161","BK1574","IBD","03681"],"gpt_icon":0},{"id":"2613711043","title":"首付款五千萬美元，和鉑醫藥一款單抗產品達成授權協議及股權合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2613711043","media":"新京报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613711043?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 21:07","pubTimestamp":1771938426,"startTime":"0","endTime":"0","summary":"节后，和铂医药再次抛出一项重磅合作。据其公告，和铂医药与SolsticeOncology（一家由多个头部风险投资机构联合创立的临床阶段生物技术公司）达成授权协议及股权合作，授予对方一款临床阶段候选产品HBM4003在大中华区以外地区的独家开发及商业化权益。这场“现金+股权”的创新合作，或将成为铂医药全球化布局的又一里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243652993770.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652993770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1574","02142","BK1161"],"gpt_icon":0},{"id":"2613005719","title":"心通醫療-B(02160.HK)股份合併生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2613005719","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613005719?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 20:47","pubTimestamp":1771937222,"startTime":"0","endTime":"0","summary":"格隆汇2月24日丨心通医疗-B(02160.HK)宣布，股份合并之全部条件已于2026年2月24日(星期二)获达成，股份合并于2026年2月24日(星期二)起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260224/32024518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1583","02160","BK1100"],"gpt_icon":0},{"id":"2613771982","title":"微創心通-B(02160)：股份合併生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2613771982","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613771982?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 20:31","pubTimestamp":1771936308,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微创心通-B(02160)发布公告，股份合并的全部条件已于2026年2月24日获达成，股份合并于2026年2月24日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1239","02160","BK1574","BK1100","BK1225","BK1583","02918"],"gpt_icon":0},{"id":"2614411657","title":"春節文旅消費創新高，復星主業基本盤穩固馬年展現強勁增長勢頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2614411657","media":"凤凰网财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614411657?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 19:46","pubTimestamp":1771933560,"startTime":"0","endTime":"0","summary":"2026年开年以来，随着创新成果的商业化落地及全球化运营的深入，复星国际核心主业延续了此前强劲的增长势头，在文旅、消费、创新药等赛道迎来新突破。文旅消费作为复星的核心主业之一，马年春节期间多条产品线展现了出强劲的增长势头。数据显示，2025年前三季度，复星医药的创新药品收入已超67亿元，同比增长18.09%。数据显示，2025年上半年，复星国际总债务占总资本比率53%，债务成本进一步下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224195109a4c2ec72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224195109a4c2ec72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1593","BK1191","BK1230","BK1574","BK1161","00656","06978"],"gpt_icon":0},{"id":"2613589714","title":"創新藥企業員工薪酬TOP100來了（附名單）","url":"https://stock-news.laohu8.com/highlight/detail?id=2613589714","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613589714?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 19:45","pubTimestamp":1771933503,"startTime":"0","endTime":"0","summary":"化学制药企业稳居人均薪酬前排。化学制剂是2024年人均薪酬最高的细分行业，头部医药企业大多来自这一领域，其中百济神州以90.10万元遥遥领先，稳居TOP1，也是唯一一家人均薪酬突破90万元的医药企业。作为创新药领域人均薪酬领先企业，百济神州2025年上半年在全球拥有一支超过3700人组成的自主临床团队，可以让其在基本无需依赖CRO的情况下开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022419560297a6da30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022419560297a6da30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1606","06978","BK1574","BK1197","BK1191","00874","BK1521","BK1515"],"gpt_icon":0},{"id":"2613718140","title":"科濟藥業-B(02171.HK)擬3月6日舉行董事會會議以審批年度業績","url":"https://stock-news.laohu8.com/highlight/detail?id=2613718140","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613718140?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 19:17","pubTimestamp":1771931828,"startTime":"0","endTime":"0","summary":"格隆汇2月24日丨科济药业-B(02171.HK)公告，董事会兹通告谨定于2026年3月6日(星期五)举行董事会会议，以考虑及通过集团截至2025年12月31日止年度的全年业绩，以及处理其他事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260224/32024300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1587","02171","BK1574","BK1585","BK1161"],"gpt_icon":0},{"id":"2613979475","title":"雲頂新耀(01952)股東特別大會通過商業化服務協議等決議案","url":"https://stock-news.laohu8.com/highlight/detail?id=2613979475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613979475?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 17:52","pubTimestamp":1771926759,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀有限公司宣布，于2026年2月24日以线上虚拟会议形式举行的股东特别大会顺利召开，会议所提呈的全部决议案均获股东正式通过。根据公告，本次股东特别大会批准、确认及追认了公司于2025年12月11日与海森生物签署的商业化服务协议及其项下拟进行的相关交易，为公司后续商业化运营及业务推进提供支持。与此同时，大会还批准了向公司管理层授出奖励安排，以及采纳2026年股份计划及相关授权限额等决议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01952","BK1574","BK1583"],"gpt_icon":0},{"id":"2613871794","title":"康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏增加特應性皮炎(AD)適應症中國上市許可申請獲受理並獲納入優先審評","url":"https://stock-news.laohu8.com/highlight/detail?id=2613871794","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613871794?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 17:49","pubTimestamp":1771926559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，旗下德镁医药有限公司已于2026年2月24日获得中国国家药品监督管理局受理磷酸芦可替尼乳膏轻中度特应性皮炎的新药上市许可申请。且该项NDA因“符合儿童生理特征的儿童用药品新品种、剂型和规格”，已获得NMPA药品审评中心批准纳入优先审评品种名单，有望加快产品AD适应症上市审评进程。此次增加AD适应症NDA获受理，是产品向多治疗领域拓展的关键里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1574","LU2488822045.USD","IE00BVYPNP33.GBP","BK1161","IE00BMCWC346.EUR","SG9999015986.USD","SG9999015978.USD","IE00BGHQDM52.EUR","BK1191","IE00BVYPNQ40.USD","BK1593","SG9999015952.SGD","SG9999004220.SGD","BK4132","159992","00867","SG9999015945.SGD","IE00BYV24P56.USD","AD"],"gpt_icon":0},{"id":"2613794848","title":"聖泉集團（605589）披露收購控股子公司尚博醫藥部分股權暨關聯交易公告，2月24日股價上漲4.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613794848","media":"中金财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613794848?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 17:44","pubTimestamp":1771926258,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于收购控股子公司济南尚博医药股份有限公司股权暨关联交易的公告》。公告显示，济南圣泉集团股份有限公司拟以自有资金429.00万美元收购英国宝欧信特有限公司持有的控股子公司济南尚博医药股份有限公司13.50%股权。本次交易完成后，圣泉集团对尚博医药的持股比例将由76.50%增至90.00%，不导致合并报表范围变更。交易构成关联交易，但不构成重大资产重组。本次交易已经公司董事会审议通过，无需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260224/32023896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","605589","09939","159938","BK1574","BK1515","BK0229"],"gpt_icon":0},{"id":"2613079623","title":"復宏漢霖(02696.HK)與雅培製藥就「漢斯狀」銷售新增許可區域","url":"https://stock-news.laohu8.com/highlight/detail?id=2613079623","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613079623?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 17:00","pubTimestamp":1771923600,"startTime":"0","endTime":"0","summary":"复宏汉霖公布，与KGBio订立修订及部分终止协议，终止就汉斯状于除印尼以外其他地区的独家许可权利。同时，公司与雅培制药Abbott订立许可协议修订本，进一步扩大该产品的许可区域，包括原先与KGBio协议的地区。新增许可区域包括亚洲、中东、非洲及东欧等共42个国家及地区。同时，公司将根据转让进展向KGBio支付合计不超过3,375万美元的里程碑款项，原KGBio许可协议中约定的监管里程碑亦有所下调。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200928110331378_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200928110331378_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1504484/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1504484/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000320264.USD","BK1191","01477","BK1574","HK0000165453.HKD","HK0000306685.HKD","HK0000320223.HKD","02696","HK0000306701.USD","BK1161"],"gpt_icon":0},{"id":"2613078795","title":"康希諾生物(06185)：曼海欣®獲得《藥品補充申請批准通知書》","url":"https://stock-news.laohu8.com/highlight/detail?id=2613078795","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613078795?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 16:42","pubTimestamp":1771922526,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 发布公告，公司已获得国家药监局出具的《药品补充申请批准通知书》，根据该通知书，国家药监局已批准公司的ACYW135群脑膜炎球菌多糖结合疫苗的适用人群年龄范围由“3月龄到3周岁儿童”扩大至“3月龄到6周岁儿童”的补充申请。曼海欣凭借其创新优势，展现出强劲的市场表现力，实现了市场占有率的不断攀升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物(06185)：曼海欣®获得《药品补充申请批准通知书》","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1515","BK1191","06185"],"gpt_icon":0},{"id":"2613796385","title":"恒瑞醫藥：1類創新藥SHR-1918注射液獲受理並納入優先審評程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2613796385","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613796385?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 16:41","pubTimestamp":1771922460,"startTime":"0","endTime":"0","summary":"2月24日丨恒瑞医药(600276.SH) 公告称，公司子公司北京盛迪医药有限公司收到国家药监局下发的《受理通知书》，公司1类创新药SHR-1918注射液的药品上市许可申请获受理，且已被纳入优先审评程序。该药品用于治疗成人和12岁及以上的未成年人纯合子家族性高胆固醇血症（HoFH）患者。SHR-1918注射液是公司自主研发的血管生成素样蛋白3（ANGPTL3）单克隆抗体，通过抑制ANGPTL3的活性，从而降低血清中的甘油三酯（TG）和LDL-C水平。截至目前，相关项目累计研发投入约2.42亿元。(A股报价延迟最少十五分钟。)新闻来源 (不包括新闻图片): 格隆汇","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250603120315070_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250603120315070_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/GLH2313304L/latest-news/GLH","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/GLH2313304L/latest-news/GLH","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1997245177.USD","LU2328871848.SGD","01276","BK0196","LU1328615791.USD","LU1023057109.AUD","LU1969619763.USD","BK1574","BK0012","LU2580892862.HKD","BK0060","LU0405327494.USD","LU1580142542.USD","LU2097828631.EUR","LU0359201612.USD","LU1781817850.SGD","LU2495084118.USD","600276","159992","LU2097828474.EUR","LU1655091616.SGD","BK0239","LU2543165471.USD","LU0359202008.SGD","LU2289578879.USD","BK1191","LU1064131003.USD","LU2097828714.EUR","LU2097828557.USD","BK0188","LU0359201885.HKD","BK1161","LU1820825898.SGD","LU1997244956.HKD","LU2148510915.USD","LU1146622755.USD","LU1064130708.USD","BK0028","BK0183","LU0405327148.USD","LU2580892789.USD","LU2488822045.USD","LU1997245094.SGD","LU2097828805.USD","LU1255011170.USD","06978"],"gpt_icon":0},{"id":"2613954527","title":"故鄉煙火經濟｜生產線滿負荷運轉，千名醫藥人春節守崗保供","url":"https://stock-news.laohu8.com/highlight/detail?id=2613954527","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613954527?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 16:33","pubTimestamp":1771921980,"startTime":"0","endTime":"0","summary":"\n                                                生产线上的机器轰鸣与药房里的温暖守候，共同织就了一张畅通无阻的药品供应网。                                                [全文]\n","market":"sh","thumbnail":"https://media.bjnews.com.cn/image/2026/02/24/5690384712296637109.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/image/2026/02/24/5690384712296637109.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1771916410129211.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1771916410129211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK1574","09939","159938","BK1515","BK1161"],"gpt_icon":0},{"id":"2613714551","title":"每日沽空追蹤 | 沛嘉醫療-B 02月24日沽空量成交2.6萬股，沽空比例為5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613714551","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613714551?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 16:30","pubTimestamp":1771921841,"startTime":"0","endTime":"0","summary":"沛嘉医疗-B北京时间02月24日，跌2.2%，卖空量成交2.6万股，较上一交易日减少25.71%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224163643a7191edb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224163643a7191edb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09996","BK1100","BK1583"],"gpt_icon":0},{"id":"2613279395","title":"智通AH統計|2月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=2613279395","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613279395?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 16:15","pubTimestamp":1771920905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止2月24日收盘，东北电气、京城机电股份、中石化油服分列AH溢价率前三位，溢价率分别为757.14%、285.62%、282.18%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-15.66%、-10.47%、-4.17%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","IE00BF5LJ272.USD","LU0140636845.USD","LU0516422952.EUR","BK1116","LU0823414551.USD","BK1560","LU2097828714.EUR","LU2226246903.HKD","LU0823039010.USD","LU0828237940.HKD","LU0511384066.AUD","BK1205","LU0823426480.USD","LU0456846285.SGD","BK1544","LU1868837722.USD","IE00B0169L03.USD","IE00BZ08YT58.USD","LU0823038988.USD","LU0531971595.HKD","00042","LU0737861772.HKD","LU0648948544.HKD","LU0106959298.USD","LU0516423091.SGD","LU0605514214.HKD","BK1610","LU0266512473.USD","LU2357125470.USD","BK1592","LU0431992006.USD","IE00BVYPNQ40.USD","LU0502904849.HKD","IE00B29SXG58.USD","IE00B3M56506.USD","LU0516422440.USD","IE0031814852.USD","LU0865486749.SGD","LU1224709979.USD","LU0106252389.USD","LU0588545904.SGD","BK1237","BK1202","LU3063872942.SGD","LU0531970944.HKD","LU0469268626.HKD","LU0509642566.USD","600860","IE00B5MMRT66.SGD","LU1152091168.USD","BK1562","BK1163","LU2294711713.HKD","002594","LU1211504680.USD","LU0348783233.USD","LU2045819591.USD","SG9999002828.SGD","IE00B031J352.USD","LU2097828474.EUR","SG9999001226.SGD","LU0501845795.SGD","LU0359201612.USD","IE0008369823.USD","IE0008368742.USD","LU0231483743.USD","LU0082770016.USD","BK1147","LU1366334578.USD","LU1769817179.HKD","LU0164939612.USD","LU1861219969.SGD","BK1214","LU1808992512.USD","IE00BD6J9T35.USD","BK1198","LU0244354667.USD","LU2125910500.SGD","LU0254981946.USD","LU1807302812.USD","LU0348827113.USD","LU2360107325.USD","LU0456854461.SGD","LU2399975544.HKD","BK1521","HK0000352291.HKD","LU2249611893.SGD","LU0543330566.HKD","LU2097828631.EUR","BK1554","LU0315179316.USD","BK1564","HK0000320223.HKD","BK1514","LU1831875114.USD","LU0594300179.USD","LU0572940350.SGD","LU0307460666.USD","LU2242644610.SGD","LU1868838027.USD","LU1046422090.SGD","SG9999015945.SGD","LU0417516738.SGD","LU0620787316.HKD","LU0384037296.USD","LU0211977185.USD","BK1537","LU0329678170.USD","BK1543","LU0314109678.HKD","BK1229","LU0640798160.USD","LU1993786604.SGD","LU0320764599.SGD","LU1880383366.USD","LU1880383440.USD","LU0979878070.USD","LU0880133367.SGD","BK1546","LU0117841782.USD","LU0417516902.SGD","LU0072913022.USD","BK1119","LU0348805143.USD","399300","LU0049853897.USD","LU0048580855.USD","LU2153592121.USD","BK1140","IE00BGHQDM52.EUR","LU0067412154.USD","LU0164880469.USD","LU0052750758.USD","LU1720050803.USD","SG9999004220.SGD","LU0164865239.USD","BK1584","BYDDY","LU0417516571.SGD","IE00B031HY20.USD","IE00BMCWC346.EUR","LU2348774022.SGD","SG9999006514.SGD","LU0791591158.USD","SG9999015986.USD","LU0819123356.HKD","LU1282649141.HKD","BK1522","BK1149","LU0823414478.USD","LU0345780281.USD","LU0791590937.USD","LU0348814723.USD","BK1576","LU0082770016.SGD","LU0289961442.SGD","LU0315178854.USD","LU2449936058.SGD","BK1135","LU0043850808.USD","LU0348816934.USD","BK1563","03143","LU0505663152.USD","LU0516423174.USD","IE00B543WZ88.USD","LU1115378108.SGD","LU0228367735.SGD","LU0561508036.HKD","LU0264606111.USD","BK1552","BK1231","BK1551","SG9999006597.SGD","LU0463099449.HKD","LU1282649067.USD","LU0572939691.SGD","SG9999015978.USD","BK1540","BK1505","LU2039709279.SGD","LU0588546209.SGD","LU0708995583.HKD","LU1251922891.USD","LU0348788117.USD","IE00BZ08YR35.GBP","LU0856984785.SGD","LU0164872284.USD","BK1112","IE00BVYPNP33.GBP","LU1226287529.USD","LU0594300419.USD","IE0034224299.USD","LU1481107354.HKD","LU2097828557.USD","LU0259732245.USD","BK1501","LU0488056044.USD","LU0890818403.SGD","IE00BPRC5H50.USD","BK1161","LU1366334651.USD","LU0540923850.HKD","LU1023057109.AUD","BK1141","LU0326950275.SGD","LU1769817096.USD","BK1183","LU1328277881.USD","LU0163747925.USD","LU0348784397.USD","BK1224","LU0359202008.SGD","LU1675838814.USD","LU0051755006.USD","LU0149721374.USD","HK0000306701.USD","LU1504937902.USD","BK1184","LU1303224171.USD","LU0329678337.USD","LU0593848301.USD","LU0061477393.USD","LU1152091754.HKD","BK1223","LU0588545490.SGD","LU0918141887.USD","LU0359201885.HKD","BK1528","159982","81211","LU1008478684.HKD","LU0175139822.USD","IE00BZ08YS42.EUR","BK1594","LU0173614495.USD","LU0819121731.USD","LU1961090484.USD","LU0797268264.HKD","BK1583","LU0084288322.USD","LU0327786744.USD","LU0456827905.SGD","LU0572944931.SGD","BK1171","LU2506951792.HKD","BK1509","00187","LU1861214812.USD","LU0868486357.SGD","LU0886674414.USD","LU0588545730.USD","LU2778985437.USD","LU0516422366.SGD","BK1503","LU0348825331.USD","LU0143863784.USD","LU1719994722.HKD","LU0289739343.SGD","LU0918141705.HKD","BK1582","LU2097828805.USD","LU0449515922.USD","SG9999014674.SGD","BK1191","LU0165289439.USD","BK1174","HK0000352382.USD","LU1188198961.HKD","SG9999002463.SGD","LU0370786039.SGD","HK0000320264.USD","LU0214875030.USD","LU0828237510.HKD","LU1242518857.USD","LU1282649810.SGD","LU0096374516.USD","LU0345780521.USD","LU1242518931.SGD","LU2476274308.USD","LU0228659784.USD","LU0589944569.HKD","LU0455707207.USD","LU1960683339.HKD","LU0266512127.USD","LU0737861699.HKD","LU0269904917.USD","LU0143863198.USD","BK1105","BK1258","LU1048596156.SGD","LU1105468828.SGD","BK1550","BK1574","LU1282648689.USD","LU0449509016.USD","LU0328353924.USD","LU0229945570.USD","HYDD.SI","BK1507","LU1868837565.USD","BK1515","LU0348735423.USD","LU0650527681.SGD","LU1813983027.USD","IE00BYV24P56.USD","LU0828238088.HKD","BK1240","LU0287142896.SGD","LU0862451753.SGD","LU0634319403.HKD","LU1794554557.SGD","LU0823426308.USD","SG9999015952.SGD","LU0054450605.USD","LU2476274720.SGD","LU0181495838.USD","LU1688375341.USD","BK1539","LU0289960550.SGD","LU0821914370.USD","LU1770034418.SGD","LU0871576103.HKD","LU0039217434.USD"],"gpt_icon":0},{"id":"2613793131","title":"先瑞達醫療－Ｂ(06669)股價下跌5.039%，現價港幣$13.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2613793131","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613793131?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 15:59","pubTimestamp":1771919940,"startTime":"0","endTime":"0","summary":"[下跌股]先瑞达医疗－Ｂ(06669) 股价在下午03:59比前收市价下跌5.039%，现股价为港币$13.38。至目前为止，今日最高价为$13.88，而最低价为$13.38。总成交量为28.3万股，总成交金额为港币$384.899万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602246298/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602246298/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1100","BK1587","06669","BK1574"],"gpt_icon":0},{"id":"2613927798","title":"浙江醫藥(600216.SH)擬參投合夥企業 投向銀髮經濟/醫藥大健康領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2613927798","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613927798?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 15:50","pubTimestamp":1771919448,"startTime":"0","endTime":"0","summary":"合伙企业由中信医疗健康股权投资私募基金管理(北京)有限公司担任普通合伙人、执行事务合伙人和基金管理人。合伙企业重点投向银发经济/医药大健康领域的目标公司，促使被投资企业价值迅速提升，实现基金的设立目标，同时尽合理商业努力获得本基金资本的增值，并努力实现全体合伙人收益的最大化，从而实现多赢的结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK1161","BK1515","600216","BK0191","09939","BK0028","BK1574","BK0239","159938"],"gpt_icon":0},{"id":"2613176402","title":"四川天府新區、金牛區公開招聘","url":"https://stock-news.laohu8.com/highlight/detail?id=2613176402","media":"成都发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613176402?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 14:23","pubTimestamp":1771914180,"startTime":"0","endTime":"0","summary":"转自：成都发布找工作的小伙伴看过来四川天府新区一大波企业公开招聘金牛区招聘街区规划师8名四川蜀道智慧交通集团有限公司校招正在报名快来看看有没有你需要的岗位四川天府新区算法工程师、项目经理、新车销售顾问……四川天府新区一大波高潜职位来啦。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-24/doc-inhnxaes3088269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1574","BK1222","09997","09996","BK1100"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":1,"totalSize":285,"code":"91000000","status":"200"}]}}